← FDA DRUG APPROVALS

FDA ANDA · ANDA091294

ABACAVIR SULFATE

Sponsor: MYLAN PHARMS INC

APPLICATION
ANDA091294
TYPE
ANDA
ORIGINAL APPROVAL
2012-06-18
LATEST ACTION
2023-04-25
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

ABACAVIR SULFATEPrescription
ABACAVIR SULFATE EQ 300MG BASE · TABLET · ORAL

Approval history

2023-04-25Labeling · Supplement 10 · standardAP
2015-12-11Manufacturing (CMC) · Supplement 3 · unknownAP
2015-12-11Labeling · Supplement 1 · standardAP
2015-12-11Labeling · Supplement 4 · standardAP
2012-06-18OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →